DDInter1491 DDInter107
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or . Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines . Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies. Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer .
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may lead to a major life threatening interaction when taken with {v} Quinestrol
Quinestrol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Pomalidomide {u} (Compound) binds {v} (Gene) TNF
TNF {u} (Gene) is bound by {v} (Compound) Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Pomalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apalutamide
Pomalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Polatuzumab vedotin
Polatuzumab vedotin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apalutamide
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elagolix
Elagolix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Pomalidomide {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apalutamide
Pomalidomide {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Methylergometrine
Methylergometrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Pomalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alfentanil
Alfentanil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cannabidiol
Cannabidiol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Pomalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Pomalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may lead to a major life threatening interaction when taken with Quinestrol and Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Pomalidomide (Compound) binds TNF (Gene) and TNF (Gene) is bound by Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Pomalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Pomalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin and Polatuzumab vedotin may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Pomalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Pomalidomide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Pomalidomide (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Methylergometrine (Compound) and Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Pomalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil and Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Pomalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide